Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

Company Overview

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients. The company is also evaluating maralixibat and other investigational therapies in additional cholestatic liver diseases, including primary biliary cholangitis and related conditions.

Founded in 2018 and headquartered in Foster City, California, Mirum serves patients through its commercial operations in the United States and international markets where its products have received regulatory approval. The company’s leadership has included David Meeker, M.D., who has served as chief executive officer and brings experience in rare-disease and specialty pharmaceutical development.

Key Stats

• Today's Range: $78.73 to $81.94
• 50-Day Range: $81.43 to $112.59
• 52-Week Range: $63.23 to $130.00
• Volume: 208,802 shs
• Average Volume: 848,215 shs
• Market Capitalization: $5.17 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $142.56
• Consensus Rating: Moderate Buy

Mirum Pharmaceuticals Stock Analysis - MarketRank™

Mirum Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 349th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Mirum Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Mirum Pharmaceuticals has a consensus price target of $142.56, representing about 75.1% upside from its current price of $81.43.

Amount of Analyst Coverage

Mirum Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.31) to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mirum Pharmaceuticals is -5.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mirum Pharmaceuticals is -5.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mirum Pharmaceuticals has a P/B Ratio of 13.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.55% of the float of Mirum Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 11.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Mirum Pharmaceuticals has recently increased by 1.77%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mirum Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Mirum Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.85

News Sentiment

Mirum Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Mirum Pharmaceuticals this week, compared to 7 articles on an average week.

Search Interest

Only 4 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,854,484.00 in company stock.

Percentage Held by Insiders

8.32% of the stock of Mirum Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Mirum Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MIRM
• CIK: 1759425
• Web: mirumpharma.com
• Phone: (650) 667-4085
• Fax: N/A
• Employees: 433
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Mirum Pharmaceuticals: $142.56
• High Price Target: $195.00
• Low Price Target: $118.00
• Potential Upside/Downside: +77.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: -139.18%
• Pretax Margin: -138.74%
• Return on Equity: -36.28%
• Return on Assets: -8.54%

Debt

• Debt-to-Equity Ratio: 1.28
• Current Ratio: 2.86
• Quick Ratio: 2.74

Sales & Book Value

• Annual Sales: $618.07 million
• Price / Sales: 8.42
• Cash Flow: $0.05 per share
• Price / Cash Flow: 1,626.74
• Book Value: $6.12 per share
• Price / Book: 13.10

Miscellaneous

• Outstanding Shares: 64,932,000
• Free Float: 59,530,000
• Market Cap: $5.21 billion
• Optionable: Optionable
• Beta: 0.61